884654-00-6

Upstream product

• 3963-62-0 2,2-Diphenylethylamine 
• 884653-96-7 di-boc-[(1S,4R)-4-(2,6-dichloro-purin-9-yl)-cyclopent-2-enyl]-amine 
• 884654-10-8 carbonic acid (1S,4R)-4-[2-chloro-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-cyclopent-2-enyl ester ethyl ester 
• 51779-32-9 iminodicarboxylic acid di-tert-butyl ester 
• 884653-97-8 (1S,2R,3S,5R)-(di-tert-butoxycarbonylamino)-5-(2,6-dichloro-purin-9-yl)-cyclopentane-1,2-diol 
• 5451-40-1 2,6-dichloro-7H-purine 
• 60176-77-4 (1S,4R)-4-hydroxy-2-cyclopentenyl acetate 
• 884654-09-5 (1S,4R)-4-[2-chloro-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-cyclopent-2-enol 
• 162254-48-0 (1R,4S)-4-(2,6-dichloro-9H-purin-9-yl)cyclopent-2-en-1-ol 
• 5451-40-1 2,6 dichloropurine 
• 60410-16-4 (1R,4S)-4-hydroxy-2-cyclopentene-1-yl acetate 
• 884653-95-6 carbonic acid (1S,4R)-4-(2,6-dichloro-purin-9-yl)-cyclopent-2-enyl ester ethyl ester 

Downstream Products

• 884652-29-3 N-{(1S,2 R,3S,4R)-4-[2-Chloro-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-2,3-dihydroxy-cyclopentyl}-propionamide 
• 884652-89-5 N-{(1S,2R,3S,4R)-4-[2-((1S,3R)-3-amino-pyrrolidin-1-yl)-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-2,3-dihydroxy-cyclopentyl}-propionamide 
• 955969-22-9 {(R)-1-[9-((1R,2S,3R,4S)-2,3-dihydroxy-4-propionylamino-cyclopentyl)-6-(2,2-diphenyl-ethylamino)-9H-purin-2-yl]-pyrrolidin-3-yl}-carbamic acid tert-butyl ester trifluoroacetate 
• 884652-46-4 cyclopropanecarboxylic acid {(1S,2R,3S,4R)-4-[2-chloro-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-2,3-dihydroxy-cyclopentyl}-amide 
• 955969-21-8 {(R)-1-[9-((1R,2S,3R,4S)-2,3-dihydroxy-4-propionylamino-cyclopentyl)-6-(2,2-diphenyl-ethylamino)-9H-purin-2-yl]-pyrrolidin-3-yl}-carbamic acid tert-butyl ester 
• 884654-01-7 (1S,2R,3S,5R)-3-(bis-(tert-butyloxycarbonyl))-amino-5-[2-chloro-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-cyclopentane-1,2-diol 

Relevant academic research and scientific papers

Organic Compounds

A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein R1, R2 and R3 are as defined herein.

Adenosine Derivatives as A2A Receptor Agonists

A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, or stereoisomers or pharmaceutically acceptable salts thereof, wherein A, U1, U2, R1a, R1b, R2 and R3 have the meanings as indicated in the specification, are useful

ORGANIC COMPOUNDS

A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein Rl, R2 and R3 are as defined herein.

ORGANIC COMPOUNDS

A compound of formula (I) and their preparation and use as pharmaceuticals wherein R1, R2 and R3 are as defined herein.

ORGANIC COMPOUNDS

A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, wherein, Rla, Rlb, R2a, R2b, U1, U2, X1, X2 and L are as defined herein.

PURINE DERIVATIVES FOR USE AS ADENOSIN A-2A RECEPTOR AGONISTS

Compounds of formula (I) in free or salt form, wherein R1, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor,